Key Highlights

• Ecolab's $0.73 quarterly Dividend trades ex-date and Record Date September 15, 2026, payable October 15, yielding approximately 1.06%.

• Ecolab has paid cash dividends on its common stock for 89 consecutive years.

• Second-quarter net sales rose 10% to $4,415.4 million, with Organic Sales growth accelerating to 5%.

• Adjusted diluted EPS increased 11% to $2.09, and management raised full-year 2026 adjusted EPS guidance to $8.05-$8.25.

Ecolab's (NYSE:ECL) $0.73 quarterly dividend trades ex-date and record date September 15, payable October 15. Adjusted diluted EPS rose 11% to $2.09, in line with the $2.08 consensus, with Global High-Tech organic sales growing 29% and Ecolab Digital sales up 27% to $121 million.

Dividend Program and Shareholder Returns

Ecolab declared a $0.73 per share quarterly dividend, payable October 15 to shareholders of record and ex-dividend date September 15. The annualized dividend is $2.92 per share. Ecolab has paid cash dividends on its common stock for 89 consecutive years, with the current rate representing a 12% increase from 2025's $0.65 quarterly level.

About the Company

Ecolab is a global provider of water, hygiene, sanitation and infection-prevention products and services, serving restaurants, hotels, hospitals, food and beverage manufacturers, industrial facilities and semiconductor producers.

Financial Performance Behind the Payout

Ecolab reported second-quarter net sales of $4,415.4 million, up 10% year over year, with organic sales growth accelerating to 5%. Reported Operating Income was $757.9 million, up 7%, with reported Operating Margin of 17.2% and organic operating margin of 18.8%, up 40 basis points. Net Income attributable to Ecolab was $534.9 million. Reported diluted EPS was $1.90, up 3%, while adjusted diluted EPS rose 11% to $2.09. Global High-Tech organic sales grew 29% and Life Sciences grew 15%, with Ecolab Digital sales up 27% to $121 million. The company repurchased approximately 1.2 million shares and raised full-year 2026 adjusted EPS guidance to $8.05-$8.25 from $8.03-$8.23.

Outlook

Continued momentum in Global High-Tech and Life Sciences, and pricing's ability to offset commodity-cost pressure in the back half of 2026, are the items management flagged as relevant to the raised full-year adjusted EPS guidance range.